RightMed PGx for Oncology

Start Testing Patients

Personalize treatment and reduce toxicity risk based on patients’ genes with RightMed® Oncology tests (1,2)

You already personalize treatment with tumor profiling – raise your standard of care to include pharmacogenomic (PGx) guided prescribing for chemotherapy and supportive care medications. RightMed for Oncology empowers you to tailor medications and dosages to match the unique genetic makeup of individual patients based on established guidelines.

OneOme can help you integrate PGx into your health system – with a 4-5 day turnaround-time at our lab, Clinical Decision Support, clinician education, member communication materials, billing options and PGx program design consulting.

Talk with a PGx Expert

Will the meds you've prescribed be safe and effective?

The RightMed Oncology test will provide you insights into how your patient may metabolize dozens of medications with PGx guidance used for chemotherapy and supportive care – including mental health, pain management and chemotherapy induced nausea and vomiting.

  • 30%

    Nearly 30% of patients treated with fluoropyrimidines experience severe toxicity – in some cases, toxicity can be fatal (3)

  • 60%

    60% of oncology patients are prescribed 1+ supportive care medication with PGx guidelines (4)

  • Exclamation Point (1)

    See the new FDA safety announcement: https://www.fda.gov/drugs/resources-information-approved-drugs/safety-announcement-fda-highlights-importance-dpd-deficiency-discussions-patients-prior-capecitabine

RightMed Oncology test portfolio

The RightMed oncology portfolio empowers innovative health systems, oncology practices and prescribers to be as focused or comprehensive as their oncology program requires. OneOme offers single and double-gene RightMed tests, the curated RightMed Oncology panel test and the original RightMed comprehensive test. All RightMed tests have a 4-5-day turnaround time at our lab.

Single Gene Tests

DPYD – test covering 5 alleles – *2A, *13, HapB3, c.2846A>T and c.557A>G – associated with fluorouracil and capecitabine.

UGT1A1 – single gene test associated with irinotecan.

TPMT/NUDT15 – double gene test associated with thiopurines.

RightMed Oncology Panel Test

New germline PGx test focused on medications and genes with relevant guidance for the prevention of chemotoxicity or to be paired with somatic testing in chemotherapy and supportive care medications – including mental health, pain management and chemotherapy-induced nausea and vomiting.

RightMed Comprehensive Panel Test

The original and most comprehensive RightMed test covers 27 genes — everything in the RightMed Oncology test plus additional genes and medications that may be relevant for your patient down the road.

Get Started

Studies show PGx may reduce risk without treatment delays

  • 28_73-80-4-7e562db6

    Reduced Risk for 5-FU

    PGx-guided prescribing in patients carrying the DPYD *2A allele reduced the risk of fluoropyrimidine-induced grade >/=3 toxicity to 28% compared to 73% in historical controls – drug-induced death reduced from 10% to 0%. (1)

  • 24_6.5-100-9276be95

    Reduced Risk for irinotecan

    UGT1A1 poor metabolizer (PM) patients received a median 30% dose reduction of irinotecan, and the incidence of febrile neutropenia was 6.5% compared to 24% in historical UGT1A1 PMs receiving full dose therapy (P = 0.04). (2)

  • 75-80-1-412d13d6

    Quick Turn-Around Time

    In a "Real-world implementation of DPYD and UGT1A1 pharmacogenomic testing in a community-based cancer center," partnering with OneOme, 75+% of patients had results prior to initiation of chemotherapy…with a median TAT of 7 calendar days including shipping. (5)

Ochsner Health + OneOme Oncology Program

“Prior to instituting a pharmacogenomics program, we had over 100 hospital days each year due to DPYD deficiencies. Patients who came in with severe toxicities from 5-FU chemotherapy.

Today we have virtually none.”

– Dr. Marc Matrana, Ochsner Health

Why Partner with OneOme for Oncology

  • [noalt]

    Clinical Decision Support

    Vantage interactive Clinical Decision Support tool provides clinicians easy access to a patient’s RightMed test results, including genetic information and insights on dozens of medications based on the patient’s genetic profile. We also offer clinician education materials, webinars and/or on-site training.

  • [noalt]

    Evidence-Based Testing

    All RightMed tests are selectively curated by a group of pharmacists and scientists using OneOme’s rigorous standards for pharmacogenomic evidence. Each sample is analyzed at OneOme’s CLIA-certified, CAP-accredited in-house laboratory. Current turnaround-time is 4-5 days at the lab.

  • [noalt]

    Program Design

    OneOme can help you design and implement a PGx program at your health system or oncology group practice. From EHR integration to workflow design to invoicing options — contact us to learn more about how we collaborate with our partners.

    Start Testing Today

References

  1. Deenen MJ, Meulendijks D, Cats A, et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol. 2016;34(3):227-34.
  2. Hulshof EC, de With M, de Man FM, et al. UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients. Eur J Cancer. 2022;162:148-57.
  3. Lesnjakovic L, Ganoci L, Bilic I, et al. DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand? Pharmacogenomics. 2023 Jan;24(2):93-106.
  4. Shugg T, Ly RC, Rowe EJ, et al. Clinical opportunities for germline pharmacogenetics and management of drug-drug interactions in patients with advanced solid tumors. JCO Precis Oncol. 2022 Feb:6:e2100312.
  5. Muldoon M, Beck M, Sebree N, et al. Real-world implementation of DPYD and UGT1A1 pharmacogenomic testing in a community-based cancer center. Clin Trans Sci. 2024 Feb; 17(2): e13704.